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Summary
Objectives: To investigate the prevalence of HPV, HPV16, and HPV16 variants in scraped cervical
cells cytologically diagnosed as normal cervical cell and in formalin-fixed, paraffin-embedded
tissues of cervical intraepithelial neoplasia II—III and squamous cervical carcinoma in Northeast
Thailand.
Methods: All samples were subjected to PCR using consensus GP5+/GP6+ primers. HPV16 was
genotyped by Southern blot hybridization and reverse line blot hybridization. The HPV16 E6 gene
was amplified and sequenced.
Results: HPV infections were found in 33.8% of normal cervical cells, 97.3% of cervical intrae-
pithelial neoplasia II—III, and 100% of squamous cervical carcinomas. The prevalence of HPV16
increased significantly with histological grade (normal cervical cell, 16.7%; cervical intraepithe-
lial neoplasia II—III, 38.9%; squamous cervical carcinoma, 75%). The most common variant found
was the Asian (As) (58.7%) followed by the European (E) lineage (41.3%). The HPV16 As lineages
showed a risk association in 73.9% of squamous cervical cancer and 57.1% of cervical intrae-
pithelial neoplasia II—III, while no increased risk was observed in the E lineages.
Conclusion: Our study demonstrates that HPV16, in particular the As variant, was the major
causative agent associated with cervical cancer in Northeast Thailand, and our study suggests
that some mutations of the E6 gene in this variant, which leads to amino acid changes, may be
more carcinogenic.
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The human papillomavirus (HPV) is a small, non-enveloped
virus with double-stranded circular DNA. Anogenital HPV
infection is usually a sexually transmitted disease. The
viruses are divided into low-risk (LR) and high-risk (HR)
groups depending on their oncogenic potential. HR HPVs
(types 16, 18, 31, 33, 35, 45, 51, 52, 58, 59, 68, 73, and
82) are considered the main risk factor for the development
of cervical cancer.1 In Thai women, HR HPV has been
detected in 57—100% of high-grade squamous intraepithelial
lesions (HSILs) and squamous cell carcinomas, and in 27.3% of
cases with low-grade squamous intraepithelial lesions (LSIL)
and 3—20% of those with normal cytology.2—6 The most
common HPV type in squamous cell carcinoma has been
shown to be HPV16 (38.4—65%) followed by HPV18, 58, 52,
and 31.2,3,7—9 In a recent study of women in Northeast Thai-
land, HPV16 was the type found most often in normal and
low-grade lesions (ASCUS (atypical cells of undetermined
significance)/LSIL) followed by HPV58.10 Women with
HPV16 infection have an estimated odds ratio of approxi-
mately 12.3 for cancer development compared to women
without HPV.4
Different types of HPV are defined as having >10% varia-
tion in specified regions of the viral genome. Viruses varying
from each other by 2—10% are referred to as subtypes and are
infrequently observed, while those differing by<2% are seen
more frequently and referred to as intratypic variants. HPV16
has been extensively sequenced to characterize variants11
and is comprised of six major groups of variants. The HPV16
prototype belongs to the European (E) group but other
variants include Asian (As), Asian American (AA), African 1
(Af1), African 2 (Af2), and North American 1 (NA1).11 Several
studies have now documented an association between HPV16
variants and the development of cervical cancer. In previous
reports, non-European variants were found to be associated
with an excess risk of cervical cancer. The HPV16 As variant
was found to be prominent in Southeast Asia; thus, the
association of this variant with cervical disease needs clar-
ification.
The HPV16 protein sequence variations that correspond
with nucleic acid variations may also affect the complex
characteristics and change biological properties, such as
immortalizing activity, transformation activity, and inactiva-
tion of tumor suppressor proteins, p53 and pRb. Host immu-
nologic recognition may also change, perhaps in association
with specific HLA haplotypes.12 Several investigations haveTable 1 Primer sequences
Primer Sequence (50—30)
b-globin
PC04 CAACTTCATCCACGTTCACC
GH20 GAAGAGCCAAGGACAGGTA
HPV
GP5+ TTTGTTACTGTGGTAGATACTAC
GP6+ GAAAAATAAACTGTAAATCATATTC
HPV16-E6
E6-F TTGAACCGAAACCGGTTAGT
E6-R GCATAAATCCCGAAAAGCAAsuggested an association of particular HPVmolecular variants
and the risk of cervical neoplasia.12—17
The aims of this study were: (1) to investigate the pre-
valence of HPV, HPV16, and HPV16 intratypic variation (var-
iants) in scraped normal cervical cells and in formalin-fixed,
paraffin-embedded tissues of abnormal squamous cervical
cells fromwomen in Northeast Thailand, by PCR using primers
GP5+/GP6+, and (2) to evaluate the association between
HPV16 infection and variant types with cervical disease
status.
Materials and methods
Specimens
Cervical cells were obtained from women participating in
routine cervical cancer screening. They were scraped with a
wooden spatula and suspended in 5 mL of cold phosphate-
buffered saline (PBS), pH 7.5. The suspended cells were
washed twice with PBS and stored at 80 8C until used.
Cytologically normal cervical cells (N = 160) diagnosed by
Pap test were selected for DNA extraction. The formalin-
fixed, paraffin-embedded cervical tissues were obtained
from women undergoing biopsy or surgery at the Obstetrics
and Gynecology Unit; these were histologically diagnosed as
cervical intraepithelial neoplasia II—III (N = 37) and squamous
cell carcinoma (N = 40). Six 5-mm-thick sections were cut
from each paraffin block for DNA extraction. The DNA was
extracted using a PuregeneTM DNA purification system (Gen-
tra, USA) following themanufacturer’s instructions. All speci-
mens were collected from Srinagarind Hospital patients who
gave informed consent. This study was approved by the Khon
Kaen University Ethics Committee for Human Research, as
per the Helsinki Declaration.
HPV detection by PCR and nested PCR
The extracted DNA was qualified by b-globin gene detection
using primers PC04 and GH20 (Table 1).31 All qualified sam-
ples were firstly subjected to PCR amplification of the L1
region of HPV16 with GP5+/GP6+ consensus primers
(Table 1).32 The PCR was carried out in 50 mL, containing
200 ng of DNA, 0.2 mmol each dNTP, 3.5 mmol MgCl2, 1 U of
Taq DNA polymerase, and 50 pmol of the GP5+/GP6+ primers.
The initial denaturation step at 94 8C for 4 min was followed
by 40 cycles of a denaturation step at 94 8C for 1 min, anSize (bp) Reference
268 31
142 32
211 19
214 P. Chopjitt et al.annealing step at 40 8C for 2 min, and an elongation step at
72 8C for 1.5 min. The final elongation step was prolonged at
72 8C for 4 min. The final amplified product was 142 bp.
Samples that failed to produce detectable PCR products
were re-amplified using the same primers in a nested
PCR format. The number of cycles in the second round
of PCR was decreased to 30, and 2.5 mL aliquots of the first
round PCR was used as the template in the second round
amplification.
HPV genotyping
The 142 bp PCR products of all HPV DNA-positive samples
were subsequently genotyped for HPV16 by Southern blot
hybridization technique using a specific biotin-labeled probe
of HPV16 for screening. The specific biotin-labeled HPV16
probe was prepared by PCR using GP5+ and biotin-labeled
GP6+ as primers, which target the L1 gene of HPV16 and
plasmid with inserted HPV16 prototype as the template. The
HPV16-positive samples were confirmed by home-brew
reverse line blot (RLB) hybridization using an HPV16-specific
oligonucleotide probe as described by van den Brule et al.18
The biotin-labeled PCR product was amplified from
extracted DNA of samples using GP5+ and biotin-labeled
GP6+ as primers. Each amplified biotin-labeled PCR product
was hybridized to the HPV16-specific oligonucleotide probe
immobilized on a membrane.
Determination of HPV16 variants
The E6 gene (nt 46—256) of HPV16 was selected for the
classification of HPV16 variants. The amplification of E6
gene mixture contained 3 mmol MgCl2, 2 U Taq DNA poly-
merase, 0.2 mmol dNTP, 10 mM of each E6 primer (Table 1),
and 200 ng of DNA template. Amplifications were started
with an initial denaturation step at 95 8C for 5 min, fol-
lowed by 40 cycles of denaturation step at 95 8C for 30 s,
an annealing step at 55 8C for 45 s, and an elongation step
at 72 8C for 1 min. A final extension step was performed at
72 8C for 7 min.19 The PCR products were purified using the
BILATEST PCR cleanup kit and subjected to automated
sequencing at the Molecular Informatic Laboratory, Hong
Kong.
The obtained nucleotide sequences of the E6 region at nt
46—256 were aligned and compared with those of the Eur-
opean prototype HPV sequence (HPV-16R) (GenBank acces-
sion No. K02718) types, available through the GenBank
database (NCBI, National Institute of health, Bethesda,
MD, USA), using the BLAST 2.0 software server (http://
www.ncbi.nih.gov/BLAST/), BioEdit, and the Mutalin pro-
gram. The HPV16 variants were classified into phylogeneticTable 2 Prevalence of HPVand HPV16 in normal scraped cervical c
CIN II—III and SCC
Samples NCC (N = 160) CIN II—III (N = 37) S
HPV-positive 33.8% (54/160) 97.3% (36/37) 1
HPV16-positive 16.7% (9/54) 38.9% (14/36)
HPV, human papillomavirus; OR, odds ratio; CI, confidence interval; NC
grade II—III; SCC, squamous cell carcinoma.classes and subclasses on the basis of their sequence varia-
tion. The prototype sequence (HPV-16R) belonging to the
European lineage was used for comparison and nucleotide
position numbering. The E6 sequence patterns used for
identification of phylogenetic classes were modified from
Yamada et al.11 as follows:
European (E): complete homology nucleotide deviated
from HPV-16R;
Asian (As): 178 nt: T!G;
African (Af1): 132 nt: G!C, 143 nt: C!G, 145 nt: G!T;
African (Af2): 109 nt: T!C, 132 nt: G!T, 143 nt: C!G,
145 nt: G!T;
North American (NA1): 145 nt: G!T; and,
Asian American (AA): 145 nt: G!T.
Statistical analysis
The association between HPV and cytologic or histologic
category was analyzed by Chi-square test using 95% confi-
dence intervals (CI).
Results
All of the samples (N = 237) were b-globin gene-positive
indicating the presence of adequate cells in the samples.
The HPV signal was detected at first round PCR in all HPV-
positive paraffin-embedded tissue samples, whereas most of
the HPV-positive scraped cervical cell samples showed the
signal in the nested PCR. HPV DNAs were found in 33.8% (54/
160) of normal cervical cells, 97.3% (36/37) of cervical
intraepithelial neoplasia II—III, and 100% (40/40) of squamous
cell carcinomas. The HPV infection rate increased signifi-
cantly with the degree of disease status (OR 149.185; 95% CI
20.193—1102.168; p = 0.000) (Table 2).
For screening for HPV16 infection, the HPV-positive sam-
ples were genotyped by Southern blot hybridization assay and
subsequently re-confirmed for HPV16 by RLB hybridization
using an HPV16-specific oligonucleotide probe. Fifty-three
subjects were positive for HPV16, which showed a significant
trend of increase with the severity of the neoplasia
( p = 0.00). HPV16 was present in 16.7% (9/54) of normal
cervical cells, 38.9% (14/36) of cervical intraepithelial neo-
plasia II—III, and 75% (30/40) of squamous cell carcinomas,
corresponding to an associated risk (OR 22.370; 95% CI 9.952—
50.283) compared to normal cervical cells with HPV16 infec-
tion (Table 2). This result demonstrates the association of
HPV infection with severe tissue abnormality. HPV16 was
significantly associated with abnormal tissue and squamous
cell carcinoma.ells and in paraffin-embedded tissue samples from patients with
CC (N = 40) p-Value OR 95% CI
00% (40/40) 0.000 149.185 20.193—1102.168
75% (30/40) 0.000 22.370 9.952—50.283
C, normal cervical cell; CIN II—III, cervical intraepithelial neoplasia
Table 3 Nucleotide sequence variation of the partial E6 gene (nt 46—256)
Ref. HPV-16R Nucleotide of E6 gene Class Predicted
amino acid
substitution1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2
0 0 0 1 1 3 3 3 3 3 3 3 4 4 6 7 7 8 8 4
3 8 9 2 4 1 2 4 5 6 7 8 3 5 1 6 8 3 8 6
A T T G A A G A A G T T G G C G T T G G
Specimen No.
NCC
6 - - - - - - - - - - - - - - - - - - - - E-P
57 - - - - - - - - - - - - - - - - - - - - E-P
18 - - - - - - - - - - - - - - - - - - - - E-P
24 - - - - - - - - - - - - - - - - - - - - E-P
37 - - - - - - - - - - - - - - - - - - - - E-P
48 - - - - - - - - - - - - - - - - - - - - E-P
49 - - - - - - - - - - - - - - - - - - - - E-3685C
13 - - - - - - - - - - - - - - - - G - - - As D25E
108 - - - - - - - - - - - - - - - - G - - - As-647G D25E
CIN II—III
2—6 - - - a - - - - - - - - - - - - - - - - E-P
2—11 - - - - - - - - - - - - - - - - - - - - E-P
2—15 - - - - - - - - - - - - - - - - - - - - E-P
2—16 - - - - - - - - - - - - - - - - G - - - As D25E
2—17 - - - - - - - - - - - - - - - - - - - - E-P
2—19 - - - - - - - - - - - - - - - - G - - - As D25E
2—25 - - - - - - - - - - - - - - - - G - - - As D25E
2—27 - - - - - - C - - - - - - - - - G - - - As-132C 10T, D25E
2—36 - - - - - - - - - - - - - - - - - - - - E-P
2—37 - - - - - - - - - - - - - - - - G - - - As D25E
2—39 - - - - - - - - - - - - - - - - G - - - As D25E
2—41 - - - - - - - - - - - - - - - - G - - - As D25E
2—42 - A - - - - - - - - - - - - - - - - - - E-108A F2Y
2—44 - - - - - - - - - - - - - - - - G - - - As D25E
SCC
1—3 - - - a - - - - - - - - - - - - G - - - As-3684A D25E
1—8 - - - - - - - - - - - - - - - - G - - - As-647G D25E
1—11 - - - - - - - - - - - - - - - - G - - - As D25E
1—13 - - - a - - - - - - - - - - G - - - As-647G D25E
1—14 - - - a - - - - - - - - - - - - G - - - As-647G D25E
1—16 - - - a - - - - - - - - - - - A G - - - As-176A D25H
1—17 - - - - - - - - - - - - - - - - G - - - As D25E
1—19 - - - - - - - - - - - - - - - - G - - - As D25E
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Table 3 (Continued )
Ref. HPV-16R Nucleotide of E6 gene Class Predicted
amino acid
substitution1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2
0 0 0 1 1 3 3 3 3 3 3 3 4 4 6 7 7 8 8 4
3 8 9 2 4 1 2 4 5 6 7 8 3 5 1 6 8 3 8 6
A T T G A A G A A G T T G G C G T T G G
1—21 - - - - - - - - - - - - - - - - G - - - As-647G D25E
1—26 - - - - - - - - - - - - - - - - G - - - As D25E
1—30 - - - - - - - - - - - - - - - - G - - - As-647G D25E
1—31 - - - a - - - - T - - - - - - - G - - - As-135T K11N, D25E
1—32 - - - - - - - - - - - - - - - - G - - - As D25E
1—34 - - - - - - - - - - - - - - - - G - - - As-647G D25E
1—35 - - - - - - - - - - - - - - - - G - - - As-647G D25E
1—37 - - - - - - - - - - - - - - - - - - - - E-P
1—38 - - - - - - - - - - - - - T - - - - - - E-145T Q14D
1—40 - - - - - - - - - - - - - T - - - - - - E-145T Q14D
1—42 - - - - - - - - - - - - - - - - G - - - As D25E
1—44 - - - C C - - - - - - - - - - - - - - - E-112C Q3H, D4A
1—45 c - - - - - - T C - - - T - - - - - - - E-134T K11Y, Q14H
1—46 - - - - - - - - - - G C - - - G - - - As-137G L12A, D25E
1—47 - - - - - - - - - - - - - - - - - - - A E-246 R48Q
HPV, human papillomavirus; HPV-16R, reference HPV16; NCC, normal cervical cell; CIN II—III, cervical intraepithelial neoplasia grade II—III; SCC, squamous cell carcinoma.
Phylogenetic classes are noted as E for European, As for Asian. ‘P’ following E refers to prototype. For subclasses, the number and the letter represent the nucleotide change at that position. At
the top, nucleotide positions where variations were detected. In the columns, predicted substitution, the letter preceding the amino acid position refers to the reference HPV16 and the letter
after refers to the substitution. The upper case; nucleotide and amino acid were changed, the lower case; nucleotide was changed but amino acid not changed.
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Table 4 Distribution of HPV16 variants in normal and abnormal cervical squamous cells
HPV16 variants Total Cervical disease severity p-Value OR 95% CI
NCC (%) CIN II—III (%) SCC (%)
E lineage 19 7 (77.8) 6 (42.9) 6 (26.1) 0.022 0.137 0.025—0.763
As lineage 27 2 (22.2) 8 (57.1) 17 (73.9) 0.022 7.292 1.311—40.542
Total 46 9 14 23
HPV, human papillomavirus; OR, odds ratio; CI, confidence interval; NCC, normal cervical cell; CIN II—III, cervical intraepithelial neoplasia
grade II—III; SCC, squamous cell carcinoma.
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Subjects with normal cervical cells (nine cases), cervical
intraepithelial neoplasia II—III (14 cases), and squamous cell
carcinomas (23 cases) who were HPV16-positive were further
investigated for intratypic variation. The amplification pro-
duct of the E6 gene at nt 46—256 was used for classification of
HPV16 variants through a comparison with the modified data
of Yamada et al.11 as described above. All identified variants
are listed in Table 3.
Among the HPV16-positive subjects, the most common
variant was the HPV16 As lineage (58.7%) found in two normal
cervical cells (22.2%), eight cervical intraepithelial neoplasia
II—III (57.1%), and 17 squamous cell carcinomas (73.9%).
Nineteen (41.3%) HPV16 E lineages presented with seven in
normal cervical cells (77.8%), six in cervical intraepithelial
neoplasia II—III (42.9%), and six in squamous cell carcinomas
(26.1%) (Table 4). Comparison using 2  2 tables with the
Fisher’s exact test of the HPV16 As lineage frequency
observed in normal cervical cells and those with cell abnorm-
alities (cervical intraepithelial neoplasia II—III and squamous
cell carcinomas), demonstrated that the HPV16 As lineage
was significantly associated with the severity of cell abnorm-
ality (OR 7.292; 95% CI 1.311—40.542; p = 0.022).
Discussion
In the present study, we investigated the prevalence of HPV
and HPV16 infection in women with a normal cytological
diagnosis and those with a histological diagnosis of cervical
intraepithelial neoplasia II—III and squamous cell carcinoma
in Northeast Thailand. Using single PCR and nested GP5+/
GP6+ PCR, the HPV DNA was detected in 33.8% of the normal
cervical cells, 97.3% of intraepithelial neoplasia II—III, and
100% of squamous cell carcinomas. This result confirms the
previous studies wherein HPV infection was found to be
associated with an increased risk of cervical disease severity,
since the rate of infection increased from normal cervical
cytology to minor cervical intraepithelial neoplasia II—III and
to squamous cell carcinoma. However, the prevalence of HPV
DNA in previous reports was lower than that found in our
study; this might be as a result of the different types of
specimen, primers, and techniques.
A meta-analysis of HPV types in invasive cervical cancer
worldwide indicated that the adjusted HPV prevalence was
significantly higher in studies using both cervical exfoliated
cells and biopsies (92.5%) than that determined using either
cervical exfoliated cells (78.9%) or fixed biopsies (83.3%).20
For PCR primers, the highest HPV prevalence was
obtained in studies using SPF10 primers (97.2%), whereasthe lowest was obtained in studies using only type-specific
PCR (74.7%). The adjusted overall HPV prevalence varied
between 77.8% and 90.1% for other primer sets, but these
differences were not statistically significant.20 For the tech-
niques of HPV DNA detection, there are many reports of HPV
DNA detection in Thai women. A study that used hybrid
capture II (HC-II) for HPV DNA detection reported that HR
HPV was detected in all cases (100%) of high-grade dysplasia
and squamous cell carcinomas, but in only 27.3% of the cases
with low-grade dysplasia and 3.4% of those with a normal
cytology.5
A population-based study using single PCR using primers
GP5+/GP6+ found that the HPV DNA prevalence in cervical
cells fromwomen in Lampang and Songkla, Thailand was 4.8%
in normal cervical cells, 61.5% in low-grade squamous intrae-
pithelial lesions, and 100% in high-grade squamous intrae-
pithelial lesions/squamous cell carcinomas. The HR HPV was
found in 2.9% of normal cytology, 53.8% of low-grade squa-
mous intraepithelial lesions, and 100% of high-grade squa-
mous intraepithelial lesions/squamous cell carcinomas.6
The nested PCR using primers GP5+/GP6+ presented a
higher sensitivity for HPV DNA detection than the single PCR.
Remmerbach et al. performed a nested PCR of GP5+/GP6+
primer systems, which increased the positivity of HPV DNA
detection from 35.8% to 65.1% in oral samples. For cervical
samples, HPV DNA was increased from 46.4% to 69.6%. These
studies support the higher rate of HPV DNA detection in our
study.21
In previous studies, HPV16 was the most common type
found in cytologically normal and in invasive cervical
cancer worldwide.22 A prevalence of 19.7% of HPV16 was
reported in 15 613 women without cervical abnormalities
in an International Agency for Research on Cancer (IARC)
HPV prevalence survey. In Asia, HPV16 was present in 18.7%
of HPV-positive women, but in 12.3% in sub-Saharan Africa,
21.4% in South America, and 25.5% in Europe.22 In our
study, 16.7% was detected in normal cervical cells, repre-
sentative of women in Northeast Thailand. Our study
suggests that these women are the risk group. A previous
study from our group reported that women infected with
HR HPV and HPV16 had an increased risk of cervical carci-
noma with an odds ratio of 130.6 (95% CI 11.7—1457.0) and
12.3 (95% CI 4.3—36.4), respectively.4 Our study also found
the prevalence of HPV16 presenting in cervical intrae-
pithelial neoplasia II—III (38.9%) and squamous cell carci-
noma (75%) corresponding to results of previous studies in
which 50—80% of HPV16 was reported in squamous cell
carcinoma.2,17,23—25
Recent reports have indicated a greater risk associated
with certain variants of HPV16 compared with others. It
218 P. Chopjitt et al.has been proposed that variants of HPV16 may differ in
incidence and outcome of infection. In our present study,
the E6 open reading frame of HPV16 variants was deter-
mined using three primer sets; however, several regions of
the E6 gene could not be amplified. It might be that the
DNA is damaged during processing of the paraffin-
embedded samples. Since E6 at nt 46—256 position was
the most common variation of HPV16 in the Asian popula-
tion and was commonly amplified, it was used for variant
classification. By the modified phylogenetic classification,
detected HPV16s were classified as E lineage (41.3%) and
As lineage (58.7%). This supports the hypothesis that HPV16
variants have a significant geographic diversity.
The As lineage was the most common variant found,
corresponding with a previous report in the Southeast Asian
population.11,15,23 Vaeteewoottacharn et al. characterized
HPV16 DNA variants in the E6 and E7 coding regions of Thai
cervical squamous cell carcinomas. A mutation T178G,
change from aspartate to glutamate (D25E), was the most
common variation accounting for 70%.26 Choi et al. inves-
tigated the genomic variation of HPV16 E6 and E7 genes
from cervical swabs of Korean commercial sex worker by
PCR. They found that the dominant HPV16 E6 and E7
variants were E6 D25E 68% and E7 N29S 73%, which belong
to the As lineage. They suggest that the distinctive dis-
tribution of HPV16 As variants E6 D25E and E7 N29S might be
associated with geographical dependence rather than dis-
ease progression.27
The E lineage was commonly found in normal cervical
cells (77.8%) as shown in Table 4, whereas the As lineage
was found at an increasing rate with increasing histologic
grade, i.e., 22.2%, 57.1%, and 73.9% in normal cervical
cells, cervical intraepithelial neoplasia II—III, and squa-
mous cell carcinomas, respectively. This result shows
the associated risk of women infected with the As lineage
(OR 7.292; 95% CI 1.311—40.542) compared with the E
lineage.
Xi et al. reported that infection with the non-European
variants is associated with a 2- to 9-fold increased risk of
cervical cancer and precancerous lesions.28 Hildesheim and
Wang determined that there was an association between
natural variants of HPV16 and the risk of biopsy-confirmed
cervical intraepithelial neoplasia II or III. The prototype-
like and non-prototype-like variants were determined by
means of single-strand conformation polymorphism (SSCP).
They suggested that the risk of developing cervical intrae-
pithelial neoplasia II—III is not the same with all variants of
HPV16 and that the non-prototype-like variant conferred a
greater risk than the prototype-like variants.29 Grodzki
et al. suggested that the HPV16 E6 variants were significant
risk factors for viral persistence and progression to a high-
grade lesion.30
In conclusion, this study found that the prevalence of
HPV and HPV16 infection is associated with an increased
risk for cervical cancer and its precursor lesions, such as
cervical intraepithelial neoplasia II—III. The As lineage of
HPV16 variants and nucleotide variations at E6 may involve
a change in the biological properties and a change in the
transforming potential, increasing the risk of cervical cancer
development. HPV16 As variants associated with disease
severity in the population of Northeast Thailand may be
important for designing a vaccine for this region.Acknowledgments
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